|
Anemia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
When compared with MPL wild-type patients, irrespective of JAK2(V617F) status, those with MPL(W515L/K), were more frequently female, were older (61 years vs. 57 years; P = 0.02), presented with more severe anaemia (haemoglobin, 101 g/l vs. 121 g/l; P = 0.002) and were more likely to require regular transfusional support (P = 0.012).
|
17408465 |
2007 |
|
Angina Pectoris
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Anorexia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Antiphospholipid Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.
|
29757439 |
2018 |
|
Aplastic Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (ELT), an oral thrombopoietin receptor agonist, has recently emerged as a promising new drug for the treatment of aplastic anemia (AA).
|
30915499 |
2019 |
|
Aplastic Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together with the recent identification of THPO receptor (MPL) mutations and the effects of THPO agonists in aplastic anemia, our results have clinical implications in the diagnosis and treatment of patients with aplastic anemia and highlight a role for the THPO-MPL pathway in hematopoiesis in vivo.
|
24085763 |
2013 |
|
Arterial thrombosis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Arthralgia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Arthritis, Psoriatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found that natively thrombocytopenic <i>Mpl</i><sup>-/-</sup> mice deficient in the thrombopoietin receptor sustain severe lung injury marked by alveolar barrier disruption and hemorrhagic pneumonia with early mortality following acute intrapulmonary <i>Pseudomonas aeruginosa</i> (PA) infection; barrier disruption was attenuated by platelet reconstitution.
|
30733303 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
|
25132654 |
2014 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
|
30191972 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
|
30854783 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.
|
31156798 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.
|
29215956 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
|
30880797 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report.
|
27671102 |
2016 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
|
31007886 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
|
29532903 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (ELT) is a thrombopoietin receptor activator that has shown efficacy in chronic immune thrombocytopenia.
|
31205222 |
2020 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
|
31818701 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
|
29848048 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
|
31280643 |
2020 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The thrombopoietin receptor (TPOR) agonist romiplostim (RP) is a therapeutic agent for immune thrombocytopenia and has potential to respond to such victims.
|
30926566 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
|
28275823 |
2017 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.
|
29293383 |
2019 |